A. Tablante Nunes

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Y. Drew, R. Plummer, P. Roxburgh, 2022, Annals of Oncology.

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

J. Jassem, P. Wysocki, P. Schmid, 2022, Annals of Oncology.